A series of disappointments that drove Sage Therapeutics Inc.’s stock down by 85% since August of 2023 has evolved into an unsolicited takeout offer by partner Biogen Inc., followed by a lawsuit filed ...

Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...

Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital ...

Billionaire investor Ken Griffin is the founder of Citadel Advisors, one of the world’s most successful alternative ...

Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...

US biotech Sage Therapeutics on Friday sued Biogen, a week after the biotech giant made an unsolicited offer to acquire the smaller neuroscience company for about $469 million, according to a ...

Humana Inc. fell short of pleading standards in its racketeering lawsuit against Biogen Inc. over its allegedly fraudulent ...

Sage (SAGE) is reportedly suing Biogen (BIIB) over enforcement of a standstill agreement in the wake of an unsolicited ...

Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...

We will be sharing Q4 2024 hedge fund investor letters in this article. You can also see the hedge fund investor letters for 2024 Q3, 2024 Q2 , 2024 Q1, 2023 Q4, 2023 Q3, 2023 Q2 and 2023 Q1 by ...

Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, specializes in discovering, developing, manufacturing, and ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target ...